Memantin Puren

Memantine Hydrochloride, the active ingredient in Memantin Puren, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients. The medication works by modulating glutamatergic activity, thereby reducing neuronal excitotoxicity associated with disease progression.

GNH USA supplies Memantin Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through stringent quality‑assurance processes and provides reliable logistics for global distribution.

Memantine, an NMDA receptor antagonist, is used in the symptomatic management of Alzheimer’s disease. - Moderate to severe Alzheimer’s disease: improves cognition, functional abilities and global clinical status in patients with established disease. - Cognitive decline in Alzheimer’s disease: helps maintain daily living activities and may slow functional deterioration. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and improve overall patient cooperation.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Nausea

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Seizures - Cardiac arrhythmias - Hepatic dysfunction - Hallucinations or psychosis - Suicidal thoughts or behavior

When prescribing Memantin Puren, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: monitor for increased seizure activity. - Concurrent use of other NMDA antagonists: avoid due to additive neurotoxicity. - Pregnancy: safety category unknown; avoid unless potential benefit justifies the risk. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Memantine can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: increased risk of central nervous system adverse effects. - Other NMDA antagonists (e.g., ketamine): additive neurotoxicity. - Strong CYP3A4 inducers such as carbamazepine or phenytoin: may markedly reduce memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish therapeutic benefit. - Diuretics (e.g., furosemide): can raise memantine levels, requiring monitoring. - Alcohol: may enhance dizziness and sedation.